The story appears on

Page A10

November 28, 2017

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Consumer

AstraZeneca forms 50-50 JV with SDIC

GLOBAL biopharmaceutical giant AstraZeneca said yesterday it had formed a joint venture with a private equity unit of China’s State Development and Investment Corporation to develop new drugs, focusing on oncology, cardiovascular, metabolic and respiratory diseases.

The 50-50 joint venture, Dizal (Jiangsu) Pharmaceutical Co Ltd, will have a registration capital of US$130 million. It holds exclusive rights to commercially develop three potential medicines already in pre-clinical development at AstraZeneca.

“We’re reinforcing with this joint venture our long-standing and strong commitment to China and we aim to accelerate the local discovery and development of innovative, affordable medicines for patients by joining forces with the SDIC Fund,” AstraZeneca Chief Executove Officer Pascal Soriot said.

AstraZeneca will also inject more capital and resources to support local research and development as well as bringing new projects to Dizal as the joint venture develops. The SDIC Fund will contribute money and expertise to establish strategic tie-ups in China.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend